An interventional study of Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®. and Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002® in Skin Manifestations, Wrinkle and Photoaging, sponsored by Botanee Group Co., Ltd.. Completed at 1 site in China. Open to female participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Botanee Group Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation treatment by comparing visual clinical scores, skin attributes measurement and image analysis.
The main expectations are:
29 studies on the registry are indexed under Skin Manifestations; 5 are open to participants now.
This study's enrollment of 24 is below the median of 75 across 23 interventional studies indexed under Skin Manifestations.
Browse Skin Manifestations studies →Botanee Group Co., Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After the 1064nm fractional picosecond laser treatment, daily use of the formulation for 56 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.
Combination Product: Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.
After the 1064nm fractional picosecond laser treatment, daily use of the blank formulation for 56 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.
Combination Product: Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®
Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
changes in skin manifestations of photodamage (global score)
Scoring by two independent dermatologists, a global score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (tactile skin roughness)
Scoring by two independent dermatologists, a roughness score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (fine lines)
Scoring by two independent dermatologists, a fine-line score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (coarse wrinkles)
Scoring by two independent dermatologists, a coarse-wrinkle score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (mottled pigmentation)
Scoring by two independent dermatologists, a pigmentation score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (erythema)
Scoring by two independent dermatologists, an erythema score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (dull skin)
Scoring by two independent dermatologists, a dull-skin score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin manifestations of photodamage (telangiectasia)
Scoring by two independent dermatologists, a telangiectasia score of facial skin on a 5-point scale (0-4) will be recorded, i.e., lower scores meaning a better outcome.
Time frame: Day 0, Day 15, Day 29, Day 57
changes in skin surface hydration(a.u.) of facial skin
measuring hydration of the stratum corneum by Corneometer® MPA580 (Courage\&Khazaka#Germany)
Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in transepidermal water loss (TEWL#in g/m2/h) of facial skin
measuring the loss of water that passes from inside a body through the epidermis to the surrounding atmosphere by Tewameter® MPA580 (Courage\&Khazaka#Germany)
Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in index of erythema of facial skin
measuring erythema by Mexameter MX18(Courage\&Khazaka, Germany)
Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in index of melanin of facial skin
measuring melanin by Mexameter MX18(Courage\&Khazaka, Germany)
Time frame: Day 0, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in individual typology angle (ITA°) of facial skin
capturing facial images by VISIA-7 (CANFIELD, America) and calculating the ITA
Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in the percentage of facial skin pore area
capturing facial images by VISIA-7 (CANFIELD, America) and calculating the percentage of pore area
Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in the characteristics of facial wrinkles (depth)
capturing facial images by VISIA-7 (CANFIELD, America), and recording the depth of wrinkles at the specific face region
Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in the characteristics of facial wrinkles
capturing facial images by VISIA-7 (CANFIELD, America), and recording the area of wrinkles at the specific face region
Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
changes in the characteristics of crow's feet
capturing facial images by Primos (CANFIELD, America) and calculating the area of crow's feet at the specific face region
Time frame: Day 0, Day 29, Day 57
safety and tolerability
Any adverse effects (e.g., erythema, flush, stinging, pruritus, and spot hemorrhage, desquamation) on both sides of face will be recorded at each visit by two independent dermatologists. The severity of the observed effect will be scored on a 5-point scale (0-4) , i.e., higher scores meaning a more severe level .
Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
self-assessment by participants
All the particpants will be asked to report any discomfort (e.g., stinging, pruritus, burning sensation) in their faces at each visit. The severity of the reported discomfort will be scored on a 5-point scale (0-4) , i.e., higher scores meaning a more severe level.
Time frame: Day 0, Day 1, Day 3, Day 5, Day 8, Day15, Day 29, Day 57
Ran from Nov 2023 to primary completion in Jan 2024, 2 months.
Of 14 interventional studies with no phase under Skin Manifestations, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Botanee Group Co., Ltd.